Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant (The Third Affiliated Hospital of Southern Medical University)
- Development stage
- Preclinical
- Lead developer
- The Third Affiliated Hospital of Southern Medical University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal, Oral, Intranasal
01
Overview
Fecal microbiota transplant (FMT) is an investigational biologic intervention being evaluated by The Third Affiliated Hospital of Southern Medical University for the treatment of type 1 diabetes mellitus. The therapy consists of fecal microbiota sourced from healthy donors, which is administered via transendoscopic enteral tubing. The primary mechanism of action is the modulation and reconstruction of the patient's intestinal micro-ecology. By altering the gut microbiome, the treatment aims to modulate the host's immune system to reduce the autoimmune-mediated destruction of pancreatic beta cells that characterizes type 1 diabetes. A clinical study (NCT04124211) is underway to assess this approach and investigate the underlying mechanisms using metagenomic and 16s rRNA sequencing technologies.
- Other names
- fecal microbiota-The Third Affiliated Hospital of Southern Medical University-type 1 diabetes mellitusFMT
Beyond the preview
Go deeper on fecal microbiota transplant (The Third Affiliated Hospital of Southern Medical University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant (The Third Affiliated Hospital of Southern Medical University).